Last reviewed · How we verify

NCT05484401

Ibuprofen Liquid Capsules 2 x 200 mg Efficacy and PK/PD Study in Surgical Removal of Impacted Third Molars

Completed Phase 3 Last updated 22 June 2023
What this trial tests

Phase 3 trial testing Ibuprofen 200Mg Oral Cap in Tooth, Impacted in 294 participants. Completed in 15 June 2023.

Timeline
9 August 2022
Primary endpoint
15 June 2023
15 June 2023

Quick facts

Lead sponsorReckitt Benckiser Healthcare (UK) Limited
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment294
Start date9 August 2022
Primary completion15 June 2023
Estimated completion15 June 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Reckitt Benckiser Healthcare (UK) Limited — full company profile →

Who can join

Adults 16 to 55, any sex, with Tooth, Impacted or Tooth Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single centre, three-arm randomised, double-blind, double-dummy, parallel group, single-dose, active and placebo-controlled efficacy and pharmacokinetics/ pharmacodynamics study to evaluate the efficacy and safety of 2 x 200 mg Ibuprofen Liquid Capsules in subjects with post-operative dental pain.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Reckitt Benckiser Healthcare (UK) Limited trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05484401.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing